Sánchez-Corredor Cristhiam David, Guerrero-Machado Mónica, Rubio-Romero Jorge Andrés, Ángel-Müller Edith, Rey-Serrano Gustavo, Díaz-Cruz Luz Amparo
Especialista en Obstetricia y Ginecología, Universidad Nacional de Colombia, Bogotá (Colombia).
Especialista en Obstetricia y Ginecología Universidad Nacional de Colombia; especialista en Cirugía Endoscópica Ginecológica, Fundación Universitaria de Ciencias de la SaludBogotáColombia.
Rev Colomb Obstet Ginecol. 2020 Dec;71(4):345-355. doi: 10.18597/rcog.3558.
To determine the prevalence of anal infection caused by high risk human papilloma virus (HR-HPV) and of abnormal anal cytology in women with confirmed cervical dysplasia.
Cross sectional study that included patients between 30 and 65 years of age with a new diagnosis of cervical dysplasia by histopathology attended in two lower genital tract colposcopy and pathology units (one public and one private institution), conducted between December 2017 and April 2019. Women with human immunodeficiency virus (HIV) infection, immune compromise (use of steroids, transplant, chemo therapy), pregnancy or anorectal malformations were excluded. Consecutive sampling. Socio demographic variables, intercourse type, degree of cervical dysplasia, positive results of HR HPV Polymerase Chain Reaction test in anal canal and HR - HPV type indentified (16-18 or others) were evaluated. Descriptive statistics were used.
Of 188 candidates, 100 were included in the analysis. A 32 % prevalence of high-risk HPV infection and a 2.8 % prevalence of abnormal cytology in the anal canal (ASCUS) were found. Of the HR-HPV infections in the anal canal, 68.8 % corresponded to HR-HPV genotypes different from 16 or 18.
Prevalence of HR HPV infection in women with lower genital tract dysplasia was 32%. It is important to determine the usefulness of screening for anal mucosa compromise by HPV virus associated with a high risk of cancer in women with cervical dysplasia. Studies are needed on the prognosis of anal HR-HPV infection in women with cervical dysplasia.
确定确诊为宫颈发育异常的女性中高危人乳头瘤病毒(HR-HPV)引起的肛门感染及肛门细胞学异常的患病率。
横断面研究,纳入2017年12月至2019年4月期间在两个下生殖道阴道镜检查和病理科(一个公立机构和一个私立机构)就诊的30至65岁经组织病理学新诊断为宫颈发育异常的患者。排除感染人类免疫缺陷病毒(HIV)、免疫功能低下(使用类固醇、移植、化疗)、妊娠或患有肛肠畸形的女性。连续抽样。评估社会人口统计学变量、性交类型、宫颈发育异常程度、肛管HR-HPV聚合酶链反应检测阳性结果及鉴定出的HR-HPV类型(16-18型或其他类型)。采用描述性统计分析。
188名候选者中,100名纳入分析。发现高危HPV感染患病率为32%,肛管细胞学异常(非典型鳞状细胞不能明确意义,ASCUS)患病率为2.8%。在肛管的HR-HPV感染中,68.8%对应于不同于16或18型的HR-HPV基因型。
下生殖道发育异常女性中HR-HPV感染患病率为32%。确定对宫颈发育异常女性筛查与癌症高风险相关的HPV病毒所致肛门黏膜损害的有用性很重要。需要对宫颈发育异常女性肛门HR-HPV感染的预后进行研究。